NAD+ vs NMN vs NR: Which Precursor Actually Works?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell and central to hundreds of metabolic reactions — energy production, DNA repair, and the activity of longevity-linked sirtuins^[7]. Its tissue levels drop progressively with age^[6], and three commercially available approaches claim to reverse that decline: nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and intravenous NAD+ infusion therapy. All three reliably raise NAD+ biomarkers in blood or skeletal muscle in humans^[1][2][4]. The honest evidence picture is more complicated: downstream clinical benefits — improvements in metabolic health, body composition, or physical function — are inconsistent and early in healthy adults; none of these products is FDA-approved for any disease; and IV NAD+, despite carrying the highest price tag, has produced zero published randomized controlled human trials. This article compares the three approaches by mechanism, human evidence, typical use, and cost — and addresses the common claim that they cause weight loss. See also our NAD+ guide for a broader overview.

The honest summary

• All three reliably raise NAD+ biomarkers. NR^[1][2], NMN^[4][5], and IV NAD+ infusion each raise measurable NAD+ or its metabolites in blood or tissue. On that narrow outcome, the evidence is consistent.
• Downstream clinical benefits are early and inconsistent. Benefits for metabolism, muscle function, or aging in healthy adults are not consistently demonstrated. Most positive signals come from small trials in specific populations (older adults, women with prediabetes). Translating a higher NAD+ level to a meaningful clinical outcome has not been reliably proven in healthy people^[6].
• NR and NMN are the best-studied orally. NR has the largest human trial dataset, including a 12-week placebo-controlled trial in 120 healthy middle-aged and older adults^[2] and studies in older skeletal muscle^[3]. NMN has published safety and pharmacokinetic data in healthy men^[5] and a rigorous trial showing improved insulin sensitivity in prediabetic women^[4].
• IV NAD+ has no published randomized controlled human trial. No peer-reviewed RCT has tested IV NAD+ infusion in humans for any outcome. The infusion is offered in private wellness clinics at significant cost with no controlled evidence to support it.
• None of these is a weight-loss drug. NAD+ precursors are not FDA-approved, not indicated for obesity, and the existing human trials do not show meaningful weight loss as an outcome in healthy or overweight adults.
• All are sold as supplements (NR, NMN) or as off-label wellness infusions (IV NAD+). As unregulated products, purity and dose consistency are not verified by any agency.

What NAD+ does — and why precursors matter

NAD+ sits at the intersection of cellular energy metabolism and signaling. In its oxidized form (NAD+) and reduced form (NADH) it shuttles electrons through glycolysis and the mitochondrial electron transport chain, directly powering ATP synthesis. But it also serves as a co-substrate for a family of enzymes central to longevity and stress-response biology: the sirtuins (SIRT1–7), which deacetylate histones and metabolic enzymes; and PARPs (poly-ADP-ribose polymerases), which consume NAD+ rapidly in DNA repair^[7]. The problem is that NAD+ does not cross cell membranes easily and is not orally bioavailable in meaningful amounts, which is why researchers have explored oral precursors that cells can convert into NAD+ — chiefly NR and NMN, both of which sit closer to NAD+ in the biosynthetic pathway than the vitamin B3 forms used in older studies (nicotinamide, niacin)^[6].

NAD+ levels measurably decline with age in blood, skeletal muscle, and other tissues^[7], and this decline has been linked to hallmarks of metabolic aging — impaired mitochondrial function, increased inflammation, and reduced sirtuin activity^[6]. That biological rationale is genuinely solid. What is less clear is whether reversing the decline pharmacologically with an oral supplement or IV infusion produces clinically meaningful benefits in people who are otherwise healthy — and that is where the human evidence is still thin.

Comparing the three approaches

Nicotinamide riboside (NR): the most-studied oral precursor

NR has the deepest human evidence base of the three. The first human trial, Trammell and colleagues in Nature Communications 2016, established that NR is orally bioavailable and dose-dependently raises whole-blood NAD+ in healthy adults — a critical proof-of-concept finding that oral supplementation could raise systemic NAD+ at all^[1]. The dose-escalation crossover study showed that single doses of 100, 300, and 1 000 mg NR all increased blood NAD+ and its metabolites without safety signals.

Martens and colleagues followed with a 12-week, placebo-controlled, randomized crossover trial in 120 healthy middle-aged and older adults published in Nature Communications 2018^[2]. The 1 g/day NR dose raised blood NAD+ metabolomics by roughly 60% versus placebo. However, the trial found no statistically significant improvements in the primary cardiometabolic outcomes — blood pressure, arterial stiffness, or vascular endothelial function — compared with placebo in this healthy, non-diseased population. The finding is important for honest framing: NR definitely raises NAD+ biomarkers in healthy adults, but that elevation did not translate to measurable cardiovascular benefit in a well-powered trial.

Elhassan and colleagues in Cell Reports 2019 examined NR in older adults with a focus on skeletal muscle^[3]. Supplementation increased skeletal-muscle NAD+ metabolomics, induced anti-inflammatory gene-expression signatures, and altered the muscle transcriptome in ways consistent with a younger metabolic phenotype — interesting mechanistic signals, though the study was primarily metabolomic and transcriptomic rather than a clinical outcomes trial. Taken together, the NR literature is internally consistent: NR reliably raises NAD+ and related metabolites; functional clinical benefits in healthy adults remain unproven.

Nicotinamide mononucleotide (NMN): promising but earlier human data

NMN sits one metabolic step closer to NAD+ than NR and gained significant public attention after a high-profile Science paper in 2021. Yoshino and colleagues published a 10-week, randomized, placebo-controlled, double-blind trial of 250 mg/day NMN in postmenopausal women with prediabetes^[4]. They found a significant improvement in skeletal-muscle insulin sensitivity and in the expression of genes related to muscle remodeling and insulin signaling — effects that were particularly robust in a subset of participants with higher post-supplementation NAD+ levels. This is the most rigorous controlled human trial of NMN to date and reported a genuine clinical signal, but in a specific population (prediabetic women, not healthy general adults or people with obesity).

Irie and colleagues in Endocrine Journal 2020 conducted an open-label, non-randomized, single-arm safety study of 100, 250, and 500 mg/day NMN for up to 12 weeks in healthy Japanese men^[5]. All doses were well-tolerated, NMN was detected in blood after oral dosing, and several blood metabolite markers shifted in expected ways — though without a placebo arm the study cannot attribute changes to NMN versus time. The study is best read as a safety and pharmacokinetics characterization, not an efficacy trial. Overall, NMN's human dataset is smaller than NR's but includes a credible metabolic-outcomes RCT in a disease-adjacent population.

IV NAD+: high cost, zero randomized controlled trial data

Intravenous NAD+ infusion therapy is offered at wellness clinics and IV-drip bars at prices that typically range from $200 to over $1 000 per session. The theoretical rationale is that IV delivery bypasses oral absorption and floods plasma with NAD+ directly. But this argument has two problems. First, NAD+ itself does not freely enter cells; cells rely on the extracellular hydrolysis of NAD+ and uptake of precursors (such as NMN or NR produced in the extracellular space) to replenish their intracellular pools — which means IV NAD+ may not be pharmacologically superior to oral precursors on a cellular-delivery basis. Second, and more critically: there are no published randomized controlled trials of IV NAD+ infusion in humans for any outcome. A PubMed search for controlled human trials of intravenous NAD+ supplementation returns no RCTs. The existing literature consists of case reports, preclinical models, and uncontrolled observational clinic series. Any claim that IV NAD+ reverses aging, boosts metabolism, or aids weight loss is not backed by controlled human trial evidence.

NAD+ precursors and weight loss: what the evidence actually says

NAD+ is central to mitochondrial energy metabolism, and its link to sirtuin signaling — which regulates fatty-acid oxidation, gluconeogenesis, and mitochondrial biogenesis — has generated excitement about its role in metabolic health^[6][7]. Animal studies have shown that boosting NAD+ can improve mitochondrial function, reduce fat accumulation, and improve insulin sensitivity in rodent obesity models. That is the basis for the weight-loss framing in wellness marketing. But the human trial data do not support meaningful weight loss in healthy or overweight adults: neither the Martens 2018 NR trial nor the Irie 2020 NMN safety study reported body weight or fat mass as significant outcomes^[2][5]. The Yoshino 2021 NMN trial showed insulin sensitivity improvements in prediabetic women but not weight loss^[4].

NAD+ is not a weight-loss drug. It is not FDA-approved for obesity or any related indication. The metabolic benefits seen in disease-adjacent human populations (prediabetes, older adults with metabolic impairment) are genuinely interesting and worth watching as the trial pipeline matures — but they have not been reproduced as weight-loss outcomes in healthy adults. If your primary goal is clinically meaningful weight loss, the evidence points toward FDA-approved GLP-1-based medications with large Phase-3 trials behind them, not toward NAD+ supplements. Discuss your options with a licensed prescriber.

Bottom line: which form should you consider?

If raising NAD+ is your goal and you want to follow the human evidence: NR and NMN are the rational starting points. NR has the broadest and most rigorous human dataset^[1][2][3]; NMN has a convincing RCT in a metabolically compromised population^[4] and a reasonable safety profile^[5]. Both reliably raise blood NAD+ metabolomics at standard doses. Neither is proven to extend lifespan, cause meaningful weight loss, or reverse aging in healthy adults — those outcomes are biologically plausible but not established by controlled human evidence. IV NAD+ has no randomized controlled trial data and costs ten to thirty times more per unit NAD+ delivered than oral precursors. The underlying premise — that IV delivery is superior — is not backed by direct human comparisons. Until a controlled trial shows IV infusion outperforms oral supplementation, paying for IV NAD+ means paying a large premium for an unproven delivery advantage. Whatever form you consider, discuss it with a physician familiar with your health history.

This article is educational and is not medical advice. Every citation is sourced to peer-reviewed literature indexed in PubMed, verified against the live PubMed database before publication. Citations 1–5 are published human trials or safety studies; citations 6–7 are expert reviews of NAD+ biology. IV NAD+ lack-of-RCT statement reflects a PubMed search for controlled human trials of intravenous NAD+ supplementation returning zero results (July 2026). Discuss any supplement or infusion therapy with a licensed prescriber before starting.